Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of argenex SE (NASDAQ:ARGX)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of argenex SE (NASDAQ:ARGX). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in argenex stock on October 15th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.

argenex Price Performance

NASDAQ:ARGX traded up $3.75 during midday trading on Thursday, reaching $981.33. 449,412 shares of the company traded hands, compared to its average volume of 423,265. The firm has a market capitalization of $61.72 billion, a price-to-earnings ratio of 34.24, a price-to-earnings-growth ratio of 0.91 and a beta of 0.48. The company has a fifty day moving average price of $925.74 and a 200 day moving average price of $860.30. argenex SE has a twelve month low of $661.85 and a twelve month high of $1,072.75.

argenex (NASDAQ:ARGX) last issued its earnings results on Friday, October 23rd. The company reported $7.80 earnings per share for the quarter, topping the consensus estimate of $7.44 by $0.36. argenex had a return on equity of 47.70% and a net margin of 31.66%. The firm had revenue of $1.75 billion for the quarter. On average, equities research analysts forecast that argenex SE will post 28.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ARGX shares. DZ Bank reiterated a “buy” rating on shares of argenex in a report on Friday, October 9th. The Goldman Sachs Group reissued a “buy” rating on shares of argenex in a report on Friday, September 25th. JPMorgan Chase & Co. restated a “buy” rating on shares of argenex in a research report on Wednesday, August 5th. Royal Bank Of Canada decreased their target price on argenex from $1,100.00 to $1,025.00 and set an “outperform” rating for the company in a research note on Tuesday, October 20th. Finally, Sanford C. Bernstein reaffirmed a “buy” rating on shares of argenex in a research note on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,158.76.

Institutional Trading of argenex

Several large investors have recently made changes to their positions in ARGX. Janus Henderson Group PLC increased its holdings in shares of argenex by 3.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock valued at $1,847,592,000 after acquiring an additional 83,568 shares during the last quarter. First Trust Advisors LP lifted its holdings in argenex by 98.9% in the 1st quarter. First Trust Advisors LP now owns 107,195 shares of the company’s stock worth $78,279,000 after purchasing an additional 53,293 shares during the last quarter. Squarepoint Ops LLC boosted its position in argenex by 314.8% during the second quarter. Squarepoint Ops LLC now owns 58,400 shares of the company’s stock worth $54,182,000 after purchasing an additional 44,321 shares during the period. Public Sector Pension Investment Board boosted its position in argenex by 40.3% during the third quarter. Public Sector Pension Investment Board now owns 118,300 shares of the company’s stock worth $113,000 after purchasing an additional 34,000 shares during the period. Finally, Peregrine Capital Management LLC acquired a new position in argenex during the second quarter valued at approximately $27,584,000. Institutional investors own 60.32% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About argenex

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.